Download The Brat that Causes Cancer - Institute of Molecular Biotechnology

Embargoed until March 23, 12.00 p.m. Eastern Time
The Brat that Causes Cancer
Institute of Molecular Biotechnology GmbH
Dr. Bohr-Gasse 3, 1030 Vienna, Austria
Tel: ++43-1-79044
Fax: ++43-1-79044/110
www.imba.oeaw.ac.at
Groundbreaking research on tumor stem cells hints at a detailed understanding of cancerous growth – and perhaps at possibilities for therapy.
At a computer screen of the Vienna, Austria, based IMBA laboratories, one can
observe in a live fruit fly Drosophila how a previously healthy cell all of a sudden
turns into a malignant one and starts to grow into an ultimately deadly tumor cell.
For the first time, researchers are also in a position to understand that a single
missing protein called Brat is responsible for the crises.
“We could in fact identify Brat, a protein that normally inhibits uncontrolled growth in
cells, to be the key in deciding whether a stem cell develops normally, or, if Brat is
missing, it turns into a tumor”, says Juergen Knoblich who led the team of scientists
whose findings will be published prominently in the next issue of the prestigious
journal ‘Cell’.
With his research, Knoblich follows up on recent discoveries that reframed the most
basic concepts of what tumors are. They are not just a bunch of cells gone wild
altogether, but rather like any organ made of highly differentiated cells. Those who
control the working and the growth of a tumor are like stem cells. Normally, when
they divide, the result is one specialized cell for the organ, while the other retains
the flexibility of stem cells and hence keeps the process of growth going in the
healthy, controlled way.
Knoblich’s team now checked a large number of proteins which are involved in
regulating growth. Among those, a singular and outstanding role is reserved for
Brat: When a cell divides, Brat is transmitted in only one of the two resulting cells.
Once the process of cell division is complete, Brat stops growth in this cell while in
the other resulting cell, which lacks Brat, further divisions and growth will occur.
With Brat, Knoblich and his team identified the very first gene that controls growth in
one of the two daughter cells of the division process. For the first time, they could
exactly trace a gene that, if it is missing, turns a normal stem cell into a tumor cell.
What makes the discovery in the tiny fly even more exciting is the fact that the
same protein can be also found in human cells.
Of course, there are still open questions. First of all, additional tests will need to
check if the same process works in human cells. However, a human homologue of
Policy regarding use: IMBA press releases may be freely reprinted and distributed via print and electronic media. Photos and illustrations are copyrighted by
IMBA, unless otherwise stated. They may be used free of charge in conjunction with this news story.
Contact:
Dr. Jürgen Knoblich
IMBA
+43 1 79044-4800
[email protected]
Dr. Heidemarie Hurtl
IMBA-IMP PR-Department
+43 1 79730-358
mobile: +43 664/8247910
[email protected]
Link:
IMBA Website
http://www.imba.oeaw.ac.at
Brat has been already suspected to be involved in tumor growth in humans. Another issue is to find out how
exactly this protein operates within the metabolism of a cell, which are the genes that it interacts with, and
how the entire regulatory system for growth ticks.
The new understanding of what makes a cell to become a tumor cell has enormous potential for research
aiming at cancer therapies, Dr. Knoblich is confident. As only a few stem cells are ultimately responsible for
tumor growth, any therapy must be specific enough to go just after those who are actually bad. With the
identification of the protein in charge, a first hook has been found to look out for a future targeted cure.
“It is like chasing a swarm of bees, or ants”, Dr. Knoblich explains. “It is worthless to catch any number of
individuals as long as you don’t get hold of the queen.”
Jürgen Knoblich
Jürgen Knoblich was born in Memmingen (Germany) in 1963. He studied Biochemistry in Tübingen and
London and gradually focussed his research interest on the development of the fruit fly Drosophila.
Following his PhD in 1994, Jürgen Knoblich went to San Francisco to carry out postdoctoral research at the
laboratory of Yuh Nung Jan at UCSF. In 1997, Dr. Knoblich moved to Vienna, Austria, where he took up a
position as Group Leader at the Research Institute of Molecular Pathology (IMP). Since 2004, he has been
Senior Scientist and Deputy Director at the Institute of Molecular Biotechnology of the Austrian Academy of
Sciences (IMBA).
Jürgen Knoblich’s contributions to developmental biology have been acknowledged by Awards from the
European associations EMBO, FEBS and ELSO.
IMBA
IMBA, the Institute of Molecular Biotechnology of the Austrian Academy of Sciences, combines basic and
applied research in the area of biomedicine. Interdisciplinary research groups work towards understanding
the fundamental molecular underpinnings of normal and pathological behavior. The ultimate aim is to
translate this knowledge into novel approaches for diagnosis, prevention and therapy of diseases. IMBA is
financed by the City of Vienna and the Austrian Government.
IMP- IMBA Research Center
The Research Institute of Molecular Pathology (IMP), established in 1988 by Boehringer Ingelheim, and the
Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), which went into operation
in 2003, have agreed on a close research collaboration. Under the name “IMP-IMBA Research Center”, the
two institutes share most of the administrative and scientific infrastructure. Together, IMBA and IMP employ
over 300 people from 30 different nations. Both institutes are members of the “Campus Vienna Biocenter”.